Amorphous and partially amorphous drug analysis and formulation takes centre stage through Synectix

14 September 2007: UK pharmaceutical firm Synectix Pharmaceutical Solutions Ltd is set to take centre stage in the formulation and analysis of amorphous and partially amorphous drugs, thanks to the launch of its comprehensive range of contract research services to support the drug development programs of pharmaceutical, biotech and healthcare companies.

Dr Mark Saunders, Development Director at Synectix comments, “poorly soluble compounds represent over 60% of drugs currently in development, which has resulted in an increased demand for amorphous drug delivery systems as companies are now turning more often to this form to improve the solubility, bioavailability and efficacy of their products. At Synectix, our scientists are at the forefront of this exciting and dynamic field, having spent many years developing novel analytical tools and methodologies to help characterise and understand the physicochemical properties of amorphous and partially amorphous drugs, as well as developing bespoke formulations to improve drug solubility and bioavailability. Through direct access to our technology-sharing platforms, we can act as an extension of our clients’ own R&D facilities, supporting their product development from concept through to creation.”

The team at Synectix combines many years experience within the pharmaceutical and biotech sectors to offer a world-class level of expertise and professionalism to a wide range of clients. The company’s business model is unique within the industry, delivering Plc standards and SME flexibility within a lean operational structure which combines the highest level of academic and industry expertise with experienced international commercial business leadership. The main attraction of this winning group is the formula of a strong, balanced executive team working in tandem with a world-renowned Scientific Advisory Board to help steer product and company development to provide real-world working solutions for its clients. The business is well-funded and 100% owned by the team, ensuring all have a vested interest and will share in the company’s success.

Dr Ken Caldicott, Chief Scientific Officer and Qualified Person (QP) at Synectix, said: “Having spent the last thirty years working in a pharmaceutical development setting, I am delighted to have the opportunity to work with such cutting-edge researchers and to help to produce workable solutions for our colleagues in the industry.”

Dr Mark Saunders is pleased the business set-up has been met with such enthusiasm: “This organisation’s work involves a very high level of scientific expertise and we are delighted it is further enhanced by ICT-led communications, enabling us to gather global knowledge of some of the best pharmaceutical minds. Our entire team is focused on working in this specialised sector and our aim is to provide our clients with a world-class and comprehensive resource for amorphous dosage form development and analysis.

This year the team plans to concentrate their efforts on European markets, with direct marketing initially to UK and Scandinavian companies. For the long term their commercial plans stretch into the US, Japan and also India for drug delivery technology design, pharmaceutical characterisation, formulation development support and particle engineering.

Synectix Pharmaceutical Solutions Ltd is based at the Tredomen Business and Technology Park, near Cardiff, UK.

Ends

For further editorial information contact Lindsey Hawker on +44 (0)7737 042493 and at Lindsey@HawkerHunt.com

Editor’s notes:

1. Synectix Pharmaceutical Solutions Ltd is an emerging biopharmaceutical Contract Research Organisation (CRO) specialising in the application of advanced analytical research tools and novel formulation strategies to facilitate the characterisation and development of amorphous and partially amorphous Active Pharmaceutical Ingredients (APIs).

2. The company is registered in England and Wales No: 06295041

3. The Company is based at Tredomen Business Park, Ystrad Mynach, Hengoed CF82 7FN and Mark Saunders can be contacted on + 44 (0) 845 084 0553, Tel (mobile): +44 (0) 7813 680602 or msaunders@synectix-pharma.com . For further information see www.synectix-pharma.com